Published on 01 January 2022

Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Ipsen

Description

The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28 days) and who participated in a previous study, 2-55-52030-726 (NCT00353496).

Citations (0)

No citations found

It looks like this dataset has no citations.

Mentions (0)

No mentions found

It looks like this dataset has not been mentioned in any sources.

Metrics

Dataset Index

0.7

FAIR Score

31%

Citations

Mentions

Metrics Over Time

Publication Details

DOI

10.25934/pr00008354

Publisher

Vivli

Assigned Domain

Subfield

Epidemiology

Field

Medicine

Domain

Health Sciences

Confidence Score

42%

Source

Scholar Data Model

Keywords

Conditions: Non Functioning Entero-pancreatic Endocrine TumourInterventions: lanreotide (Autogel formulation)

Normalization Factors

15.38

CTw

1.00

MTw

1.00